Only posting this update because it validates what I said yesterday that results/data don’t justify the huge drop!
$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial evaluating the combination of the company's drug candidates lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
Data from the MYTHIC trial showed that Lunresertib, when combined with Camonsertib, resulted in promising response rates, including a 25.9 percent overall response rate (ORR) in endometrial cancer and a 37.5 percent ORR in platinum-resistant ovarian cancer.
The company plans to initiate a registrational Phase 3 Lunre+Camo trial in endometrial cancer in 2025.
The company showcased positive updated safety and tolerability data from the MYTHIC trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024.
The data revealed the benefits of an individualized dosing schedule for managing anemia. Importantly, dose optimization reduced Grade 3 anemia to 22.6 percent, down from 51.4 percent, without any instances of thrombocytopenia or serious neutropenia.
Repare also provided insight into its ongoing research with Camonsertib (RP-3500), a promising ATR inhibitor, currently being studied in non-small cell lung cancer (NSCLC) as a monotherapy and in combination with radiation therapy for tumors harboring ATM mutations.
As of September 30, 2024, Repare had cash, cash equivalents, and marketable securities totaling $179.4 million. The company expects this capital to fund its operations into the second half of 2026.
Repare is focused on advancing its clinical-stage oncology programs, following a strategic reprioritization in August 2024, which included a workforce reduction of approximately 25 percent, primarily from its preclinical group.
RPTX closed Thursday's trading at $3.97, up 10.28%. In premarket trading today, the stock is down 37.27% at $2.49.
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial evaluating the combination of the company's drug candidates lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
Data from the MYTHIC trial showed that Lunresertib, when combined with Camonsertib, resulted in promising response rates, including a 25.9 percent overall response rate (ORR) in endometrial cancer and a 37.5 percent ORR in platinum-resistant ovarian cancer.
The company plans to initiate a registrational Phase 3 Lunre+Camo trial in endometrial cancer in 2025.
The company showcased positive updated safety and tolerability data from the MYTHIC trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024.
The data revealed the benefits of an individualized dosing schedule for managing anemia. Importantly, dose optimization reduced Grade 3 anemia to 22.6 percent, down from 51.4 percent, without any instances of thrombocytopenia or serious neutropenia.
Repare also provided insight into its ongoing research with Camonsertib (RP-3500), a promising ATR inhibitor, currently being studied in non-small cell lung cancer (NSCLC) as a monotherapy and in combination with radiation therapy for tumors harboring ATM mutations.
As of September 30, 2024, Repare had cash, cash equivalents, and marketable securities totaling $179.4 million. The company expects this capital to fund its operations into the second half of 2026.
Repare is focused on advancing its clinical-stage oncology programs, following a strategic reprioritization in August 2024, which included a workforce reduction of approximately 25 percent, primarily from its preclinical group.
RPTX closed Thursday's trading at $3.97, up 10.28%. In premarket trading today, the stock is down 37.27% at $2.49.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : I did my research on platinum resistant ovarian ca and typical PFS is 3-4 months so this >7 months is good. The endometrial cancer was not much specified on its type
TranceHead : @Jaguar8 @Trytosaveabit i think because digital media made trading so easy, it's too easy for people who can't properly read a PR or announcement to trade. so we get dumb shit happen
Wave_Rider : not sure if it works for the cancer, but the diarrhea of this stock doesnt stop